Biologic therapy and risk of infection.

Rachel Gordon, Rana Mays, Hung Doan, Whitney Lapolla, Stephen K. Tyring

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Biologic compounds are being used more frequently to treat a multitude of systemic inflammatory conditions. These novel compounds are composed of antibodies or other peptides that act through one of three mechanisms: inhibiting inflammatory cytokine signaling (typically tumor necrosis factor or TNF), inhibiting T-cell activation, or depleting B-cells. The increase in use and ever expanding list of new immune modulating therapies make knowledge of the infectious complications associated with immune modulation even more important. Of particular concern is the risk for developing atypical and opportunistic infections including tuberculosis, herpes zoster, Legionella pneumophila, and Listeria monocytogenes.

Original languageEnglish (US)
Pages (from-to)1-4
Number of pages4
JournalSkin therapy letter
Volume17
Issue number4
StatePublished - Apr 2012
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Biologic therapy and risk of infection.'. Together they form a unique fingerprint.

Cite this